Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| C4 Therapeutics, Inc.CCCC · Entity 5503 | Chief Business Officer | February 13, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
C4 Therapeutics, Inc.
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 307,805 |
Reported balance
After 2026-02-13 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-02-13 · Grant · Acquired 200,000 · Balance 307,805 F1: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 100,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 100,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones. |
| Common StockSEC Table I · non-derivative | Direct | 307,805 |
Reported balance
After 2026-02-13 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-02-13 · Exercise / conversion · Acquired 5,000 · Balance 307,805 F2: Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 306,070 |
Reported balance
After 2026-02-13 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-02-13 · Tax withholding · Disposed 1,735 · Balance 306,070 F3: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. |
| Common StockSEC Table I · non-derivative | Direct | 306,070 |
Reported balance
After 2026-02-14 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-02-14 · Exercise / conversion · Acquired 20,950 · Balance 306,070 F2: Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 298,801 |
Reported balance
After 2026-02-14 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2026-02-14 · Tax withholding · Disposed 7,269 · Balance 298,801 F2: Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 100,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 100,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.
F2: Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025.
F3: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2026 Filed Feb 18, 2026 17:05 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 7,269 | $1.89 | $13,738.41 |
DisclosureSEC source: 0001470831-26-000180 · wk-form4_1771452315.xml · nonDerivative · entry 5 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 298,801 F2 · kind: Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 17:05 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 20,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000180 · wk-form4_1771452315.xml · nonDerivative · entry 4 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 306,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 17:05 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 1,735 | $1.89 | $3,279.15 |
DisclosureSEC source: 0001470831-26-000180 · wk-form4_1771452315.xml · nonDerivative · entry 3 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 306,070 F3 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 17:05 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000180 · wk-form4_1771452315.xml · nonDerivative · entry 2 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 307,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 17:05 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000180 · wk-form4_1771452315.xml · nonDerivative · entry 1 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 307,805 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 100,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 100,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones. Read SEC document |
| February 18, 2025 Filed Feb 18, 2025 16:55 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 669 | $3.15 | $2,107.35 |
DisclosureSEC source: 0001662579-25-000019 · wk-form4_1739915710.xml · nonDerivative · entry 5 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,805 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2024. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 16:55 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 84,700 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001662579-25-000019 · wk-form4_1739915710.xml · derivative · entry 6 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,700 Underlying: Common Stock · 84,700 shares Expires 2035-02-13 F4 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in forty-eight equal monthly installments following the grant date, with the first installment vesting on March 14, 2025. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 16:55 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 2,368 | $3.18 | $7,530.24 |
DisclosureSEC source: 0001662579-25-000019 · wk-form4_1739915710.xml · nonDerivative · entry 4 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,474 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 16:55 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 490 | $3.15 | $1,543.50 |
DisclosureSEC source: 0001662579-25-000019 · wk-form4_1739915710.xml · nonDerivative · entry 3 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,842 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2024. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 16:55 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 56,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-25-000019 · wk-form4_1739915710.xml · nonDerivative · entry 2 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,332 F2 · shares: Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2026. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 16:55 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 1,735 | $3.20 | $5,552.00 |
DisclosureSEC source: 0001662579-25-000019 · wk-form4_1739915710.xml · nonDerivative · entry 1 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,832 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 16:17 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000104 · wk-form4_1731446256.xml · derivative · entry 3 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 3,750 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 16:17 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 1,102 | $6.04 | $6,656.08 |
DisclosureSEC source: 0001662579-24-000104 · wk-form4_1731446256.xml · nonDerivative · entry 2 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,567 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 16:17 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-24-000104 · wk-form4_1731446256.xml · nonDerivative · entry 1 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 17:12 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000083 · wk-form4_1726607550.xml · derivative · entry 3 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 2,250 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 17:12 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 661 | $6.36 | $4,203.96 |
DisclosureSEC source: 0001662579-24-000083 · wk-form4_1726607550.xml · nonDerivative · entry 2 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,919 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 17:12 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-24-000083 · wk-form4_1726607550.xml · nonDerivative · entry 1 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 19:28 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000032 · wk-form4_1709944127.xml · derivative · entry 2 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2032-01-02 F1 · kind: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on January 3, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 19:28 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Disposition to issuerStock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $33.23 | $0.00 |
DisclosureSEC source: 0001662579-24-000032 · wk-form4_1709944127.xml · derivative · entry 1 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 115,000 shares Expires 2032-01-02 F1 · kind: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on January 3, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 17:03 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 122,800 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001662579-24-000015 · wk-form4_1708034573.xml · derivative · entry 3 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,800 Underlying: Common Stock · 122,800 shares Expires 2034-02-13 F3 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2024. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 17:03 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 27,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000015 · wk-form4_1708034573.xml · nonDerivative · entry 2 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,330 F2 · shares: Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2025. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 17:03 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 1,735 | $6.53 | $11,329.55 |
DisclosureSEC source: 0001662579-24-000015 · wk-form4_1708034573.xml · nonDerivative · entry 1 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,030 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person. Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 19:23 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001662579-23-000099 · wk-form4_1695165770.xml · derivative · entry 1 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2033-09-17 F1 · derivative.exercise_date: This option shall vest in full on September 18, 2025, subject to the Reporting Person's continued service on such date. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 16:09 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000081 · wk-form4_1693512585.xml · derivative · entry 3 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 2,250 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 16:09 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 661 | $2.93 | $1,936.73 |
DisclosureSEC source: 0001662579-23-000081 · wk-form4_1693512585.xml · nonDerivative · entry 2 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,765 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 16:09 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-23-000081 · wk-form4_1693512585.xml · nonDerivative · entry 1 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 16:45 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0001662579-23-000037 · wf-form4_167649750908844.xml · derivative · entry 2 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2033-02-12 F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 13, 2023. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 16:45 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000037 · wf-form4_167649750908844.xml · nonDerivative · entry 1 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,176 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 13, 2024. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 16:10 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000022 · wf-form4_167528579820409.xml · derivative · entry 3 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 3,750 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 16:10 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 1,222 | $7.78 | $9,507.16 |
DisclosureSEC source: 0001662579-23-000022 · wf-form4_167528579820409.xml · nonDerivative · entry 2 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,176 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 16:10 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-23-000022 · wf-form4_167528579820409.xml · nonDerivative · entry 1 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 26, 2022 Filed Jun 14, 2022 16:45 UTC Amendment | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 1,102 | $7.01 | $7,725.02 |
DisclosureSEC source: 0001209191-22-036711 · doc4a.xml · nonDerivative · entry 1 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,648 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of performance restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| May 25, 2022 Filed May 27, 2022 16:15 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032510 · doc4.xml · derivative · entry 2 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 3,750 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 25, 2022 Filed May 27, 2022 16:15 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-032510 · doc4.xml · nonDerivative · entry 1 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.